{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T02:49:29Z","timestamp":1761965369733,"version":"3.37.3"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T00:00:00Z","timestamp":1659657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T00:00:00Z","timestamp":1659657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Indian J Surg Oncol"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s13193-022-01611-w","type":"journal-article","created":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T05:02:32Z","timestamp":1659675752000},"page":"21-27","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Surgical and Oncological Outcomes after Neoadjuvant Therapy for Non-Metastatic Gastric GISTs"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7223-7555","authenticated-orcid":false,"given":"Amr","family":"Abouzid","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Setit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziad","family":"Emarah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mosab","family":"Shetiwy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,5]]},"reference":[{"issue":"1","key":"1611_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12889-018-5131-4","volume":"18","author":"M Ressing","year":"2018","unstructured":"Ressing M, Wardelmann E, Hohenberger P, Jakob J, Kasper B, Emrich K, Zeissig SR (2018) Strengthening health data on a rare and heterogeneous disease: sarcoma incidence and histological subtypes in Germany. BMC Public Health 18(1):1\u201311. https:\/\/doi.org\/10.1186\/s12889-018-5131-4","journal-title":"BMC Public Health"},{"issue":"1","key":"1611_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s10120-015-0526-8","volume":"19","author":"T Nishida","year":"2016","unstructured":"Nishida T, Blay JY, Hirota S, Kitagawa Y, Kang YK (2016) The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines. Gastric Cancer 19(1):3\u201314. https:\/\/doi.org\/10.1007\/s10120-015-0526-8","journal-title":"Gastric Cancer"},{"issue":"5350","key":"1611_CR3","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1126\/science.279.5350.577","volume":"279","author":"S Hirota","year":"1998","unstructured":"Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kitamura Y (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279(5350):577\u2013580. https:\/\/doi.org\/10.1126\/science.279.5350.577","journal-title":"Science"},{"issue":"14","key":"1611_CR4","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1056\/NEJM200104053441404","volume":"344","author":"H Joensuu","year":"2001","unstructured":"Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, Demetri GD (2001) Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344(14):1052\u20131056. https:\/\/doi.org\/10.1056\/NEJM200104053441404","journal-title":"N Engl J Med."},{"issue":"5","key":"1611_CR5","doi-asserted-by":"publisher","first-page":"536","DOI":"10.6004\/jnccn.2018.0025","volume":"16","author":"M Von Mehren","year":"2018","unstructured":"Von Mehren M, Randall RL, Benjamin RS, Boles S, Bui MM, Ganjoo KN, Scavone JL (2018) Soft tissue sarcoma, version 2.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 16(5):536\u2013563. https:\/\/doi.org\/10.6004\/jnccn.2018.0025","journal-title":"J Natl Compr Canc Netw"},{"key":"1611_CR6","doi-asserted-by":"publisher","first-page":"iv51","DOI":"10.1093\/annonc\/mdy096","volume":"29","author":"PG Casali","year":"2018","unstructured":"Casali PG, Abecassis N, Bauer S, Biagini R, Bielack S, Bonvalot S, Blay JY (2018) Soft tissue and visceral sarcomas: ESMO\u2013EURACAN Clinical Practice Guidelines for diagnosis, treatment, and follow-up. Ann Oncol 29:iv51\u2013iv67. https:\/\/doi.org\/10.1093\/annonc\/mdy096","journal-title":"Ann Oncol"},{"issue":"3","key":"1611_CR7","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1002\/cncr.23199","volume":"112","author":"RP DeMatteo","year":"2008","unstructured":"DeMatteo RP, Gold JS, Saran L, G\u00f6nen M, Liau KH, Maki RG, Antonescu CR (2008) Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer: Interdiscip Int J Am Cancer Soc 112(3):608\u2013615","journal-title":"Cancer: Interdiscip Int J Am Cancer Soc"},{"issue":"3","key":"1611_CR8","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92(3):205\u2013216. https:\/\/doi.org\/10.1093\/jnci\/92.3.205","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"1611_CR9","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1159\/000493405","volume":"34","author":"J Jakob","year":"2018","unstructured":"Jakob J, Hohenberger P (2018) Neoadjuvant therapy to downstage the extent of resection of gastrointestinal stromal tumors. Visc Med 34(5):359\u2013365. https:\/\/doi.org\/10.1159\/000493405","journal-title":"Visc Med"},{"issue":"2","key":"1611_CR10","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1245\/s10434-012-2647-1","volume":"20","author":"J Jakob","year":"2013","unstructured":"Jakob J, Mussi C, Ronellenfitsch U, Wardelmann E, Negri T, Gronchi A, Hohenberger P (2013) Gastrointestinal stromal tumor of the rectum: results of surgical and multimodality therapy in the era of imatinib. Ann Surg Oncol 20(2):586\u2013592. https:\/\/doi.org\/10.1245\/s10434-012-2647-1","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"1611_CR11","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1002\/bjs.9818","volume":"102","author":"MJ Wilkinson","year":"2015","unstructured":"Wilkinson MJ, Fitzgerald JEF, Strauss DC, Hayes AJ, Thomas JM, Messiou C, Judson I (2015) Surgical treatment of gastrointestinal stromal tumor of the rectum in the era of imatinib. Br J Surg 102(8):965\u2013971. https:\/\/doi.org\/10.1002\/bjs.9818","journal-title":"Br J Surg"},{"issue":"5","key":"1611_CR12","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1097\/COC.0b013e3182a78de9","volume":"38","author":"J Stiekema","year":"2015","unstructured":"Stiekema J, Kol S, Cats A, Yazdi AT, van Coevorden F, van Sandick JW (2015) Surgical treatment of gastrointestinal stromal tumors located in the stomach in the imatinib era. Am J Clin Oncol 38(5):502\u2013507. https:\/\/doi.org\/10.1097\/COC.0b013e3182a78de9","journal-title":"Am J Clin Oncol"},{"key":"1611_CR13","doi-asserted-by":"publisher","unstructured":"C Yoo, MH Ryu, BW Kang, SK Yoon, BY Ryoo, HM Chang, YK Kang (2010). A cross-sectional study of imatinib plasma trough levels in patients with advanced gastrointestinal stromal tumors: impact of gastrointestinal resection on exposure to imatinib. J Clin Oncol\u00a028(9). https:\/\/doi.org\/10.1200\/JCO.2009.26.5785.","DOI":"10.1200\/JCO.2009.26.5785"},{"key":"1611_CR14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ejca.2015.12.029","volume":"57","author":"S Bouchet","year":"2016","unstructured":"Bouchet S, Poulette S, Titier K, Moore N, Lassalle R, Abouelfath A, Molimard M (2016) Relationship between imatinib trough concentration and outcomes in the treatment of advanced gastrointestinal stromal tumors in a real-life setting. Eur J Cancer 57:31\u201338. https:\/\/doi.org\/10.1016\/j.ejca.2015.12.029","journal-title":"Eur J Cancer"},{"issue":"6","key":"1611_CR15","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1002\/bjs.10104","volume":"103","author":"T H\u00f8lmebakk","year":"2016","unstructured":"H\u00f8lmebakk T, Bjerkehagen B, Boye K, Bruland \u00d8, Stoldt S, Sundby Hall K (2016) Definition and clinical significance of tumor rupture in gastrointestinal stromal tumors of the small intestine. Br J Surg 103(6):684\u2013691. https:\/\/doi.org\/10.1002\/bjs.10104","journal-title":"Br J Surg"},{"issue":"4","key":"1611_CR16","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.ejso.2013.12.020","volume":"40","author":"S Bauer","year":"2014","unstructured":"Bauer S, Rutkowski P, Hohenberger P, Miceli R, Fumagalli E, Siedlecki JA, Gronchi A (2014) Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib\u2013analysis of prognostic factors (EORTC-STBSG collaborative study). EurJ Surg Oncol 40(4):412\u2013419. https:\/\/doi.org\/10.1016\/j.ejso.2013.12.020","journal-title":"EurJ Surg Oncol"},{"issue":"1","key":"1611_CR17","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/bjc.2017.144","volume":"117","author":"Y Kurokawa","year":"2017","unstructured":"Kurokawa Y, Yang HK, Cho H, Ryu MH, Masuzawa T, Park SR, Kang YK (2017) Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumors of the stomach. Br J Cancer 117(1):25\u201332. https:\/\/doi.org\/10.1038\/bjc.2017.144","journal-title":"Br J Cancer"},{"issue":"9","key":"1611_CR18","doi-asserted-by":"publisher","first-page":"2937","DOI":"10.1245\/s10434-013-3013-7","volume":"20","author":"P Rutkowski","year":"2013","unstructured":"Rutkowski P, Gronchi A, Hohenberger P, Bonvalot S, Sch\u00f6ffski P, Bauer S, Van Coevorden F (2013) Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience. Ann Surg Oncol 20(9):2937\u20132943. https:\/\/doi.org\/10.1245\/s10434-013-3013-7","journal-title":"Ann Surg Oncol."},{"issue":"7","key":"1611_CR19","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1002\/jso.23562","volume":"109","author":"H Liu","year":"2014","unstructured":"Liu H, Yan Z, Liao G, Yin H (2014) Treatment strategy of rectal gastrointestinal stromal tumor (GIST). J Surg Oncol 109(7):708\u2013713. https:\/\/doi.org\/10.1002\/jso.23562","journal-title":"J Surg Oncol."},{"issue":"1","key":"1611_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2407-14-156","volume":"14","author":"TK Huynh","year":"2014","unstructured":"Huynh TK, Meeus P, Cassier P, Bouch\u00e9 O, Lardi\u00e8re-Deguelte S, Adenis A, Duffaud F (2014) Primary localized rectal\/pararectal gastrointestinal stromal tumors: results of surgical and multimodal therapy from the French Sarcoma group. BMC Cancer 14(1):1\u20139. https:\/\/doi.org\/10.1186\/1471-2407-14-156","journal-title":"BMC Cancer"},{"issue":"1","key":"1611_CR21","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/jso.21160","volume":"99","author":"BL Eisenberg","year":"2009","unstructured":"Eisenberg BL, Harris J, Blanke CD, Demetri GD, Heinrich MC, Watson JC, Von Mehren M (2009) Phase II trial of neoadjuvant\/adjuvant imatinib mesylate (IM) for advanced primary and metastatic\/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132\/ACRIN 6665. J Surg Oncol 99(1):42\u201347. https:\/\/doi.org\/10.1002\/jso.21160","journal-title":"J Surg Oncol."},{"issue":"24","key":"1611_CR22","doi-asserted-by":"publisher","first-page":"3969","DOI":"10.1200\/JCO.2008.21.3330","volume":"27","author":"A Le Cesne","year":"2009","unstructured":"Le Cesne A, Van Glabbeke M, Verweij J, Casali PG, Findlay M, Reichardt P, Blay JY (2009) Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial. J Clin Oncol 27(24):3969. https:\/\/doi.org\/10.1200\/JCO.2008.21.3330","journal-title":"J Clin Oncol"},{"issue":"13","key":"1611_CR23","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1200\/JCO.2006.07.3049","volume":"25","author":"H Choi","year":"2007","unstructured":"Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, Benjamin RS (2007) Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25(13):1753\u20131759. https:\/\/doi.org\/10.1200\/JCO.2006.07.3049","journal-title":"J Clin Oncol"},{"key":"1611_CR24","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.humpath","volume":"62","author":"S Huss","year":"2017","unstructured":"Huss S, Pasternack H, Ihle MA, Merkelbach-Bruse S, Heitk\u00f6tter B, Hartmann W, Wardelmann E (2017) Clinicopathological and molecular features of a large cohort of gastrointestinal stromal tumors (GISTs) and review of the literature: BRAF mutations in KIT\/PDGFRA wild-type GISTs are rare events. Hum Pathol 62:206\u2013214. https:\/\/doi.org\/10.1016\/j.humpath","journal-title":"Hum Pathol"},{"issue":"6","key":"1611_CR25","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1586\/14737140.2015.1032941","volume":"15","author":"S Huss","year":"2015","unstructured":"Huss S, Elges S, Trautmann M, Sperveslage J, Hartmann W, Wardelmann E (2015) Classification of KIT\/PDGFRA wild-type gastrointestinal stromal tumors: implications for therapy. Expert Rev Anticancer Ther 15(6):623\u2013628. https:\/\/doi.org\/10.1586\/14737140.2015.1032941","journal-title":"Expert Rev Anticancer Ther."},{"issue":"3","key":"1611_CR26","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S1470-2045(11)70299-6","volume":"13","author":"H Joensuu","year":"2012","unstructured":"Joensuu H, Vehtari A, Riihim\u00e4ki J, Nishida T, Steigen SE, Brabec P, Rutkowski P (2012) Risk of recurrence of gastrointestinal stromal tumor after surgery: an analysis of pooled population-based cohorts. Lancet Oncol 13(3):265\u2013274. https:\/\/doi.org\/10.1016\/S1470-2045(11)70299-6","journal-title":"Lancet Oncol"}],"container-title":["Indian Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13193-022-01611-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13193-022-01611-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13193-022-01611-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T04:30:50Z","timestamp":1678077050000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13193-022-01611-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,5]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["1611"],"URL":"https:\/\/doi.org\/10.1007\/s13193-022-01611-w","relation":{},"ISSN":["0975-7651","0976-6952"],"issn-type":[{"type":"print","value":"0975-7651"},{"type":"electronic","value":"0976-6952"}],"subject":[],"published":{"date-parts":[[2022,8,5]]},"assertion":[{"value":"13 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approval was obtained from the Institutional Research Board (IRB) of the Faculty of Medicine, Mansoura University, code R.21.02.1229. Written informed consent was obtained from all the patients included in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}